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ORIGINAL ARTICLE
Survival of patients with subglottic  
squamous cell carcinoma
S.D. MacNeil md msc,*† K. Patel md,* K. Liu,† S. Shariff phd,† J. Yoo md,* A. Nichols md,* K. Fung md,* 
and A.X. Garg md phd†‡§
ABSTRACT
Objective Subglottic squamous cell carcinoma is a rare subsite of laryngeal cancer that behaves more aggressively 
and portends a worse prognosis. Using a population-based cancer registry, our objective was to report overall survival 
(os) and laryngectomy-free survival (lfs) in patients diagnosed with subglottic squamous cell carcinoma, and to 
determine whether primary laryngectomy results in improved survival.
Methods This retrospective population-based study considered patients with a new diagnosis of squamous cell 
carcinoma in the province of Ontario over a 15-year period (1995–2009). The Ontario Cancer Registry was examined 
for patients with the diagnosis of interest during the period of interest. Linked population-based databases were used 
to obtain patient demographics, comorbidity measures, staging, survival, and primary treatment with laryngectomy.
Results Of 4927 patients identified to have laryngeal carcinoma, 89 were defined as having primary subglottic 
carcinoma (1.8%). In the subglottic cohort, 68 patients were men (76.4%), and mean age at diagnosis was 68 years 
(interquartile range: 60–77 years). The 5-year os was 47.2%, and the 5-year lfs was 31.5%. In 13 patients (15%), the 
primary treatment was laryngectomy, which, compared with primary radiation, did not predict for improved os. No 
differences in os or lfs were observed during the 15-year study period (os p = 0.42, lfs p = 0.83).
Conclusions The survival of patients with subglottic carcinoma is poor and has remained stable over time (1995–
2009). Compared with primary radiation, primary treatment with laryngectomy does not appear to improve os.
Key Words Head-and-neck cancer, larynx, radiation therapy, outcomes
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INTRODUCTION
Squamous cell carcinoma (scc) of the subglottis is rare, 
representing less than 5% of all laryngeal cancer1,2. In the 
past, separating primary subglottic cancer from glottic 
cancer with subglottic extension was challenging because 
of poor imaging and laryngoscopy equipment3. The su-
perior anatomic boundary of the subglottis has also been 
inconsistently defined, ranging from 5 mm to 1 cm below 
the lateral margin of the ventricle, further complicating ac-
curate classification of this disease subsite4. The rarity of the 
disease, the historic difficulty in separating primary from 
secondary subglottic cancer, and the changing definition of 
the superior boundary have made it challenging to report 
treatment and survival outcomes for this rare carcinoma.
Secondary to advanced stage at presentation, pro-
pensity for paratracheal and upper mediastinal lymphatic 
spread, and increased risk of stomal recurrence, primary 
subglottic scc is thought to herald a prognosis worse than 
that for other subsites of laryngeal cancer5–9. Historically, 
total laryngectomy has been the standard of care for the 
treatment of subglottic carcinoma3. More recent retro-
spective studies have demonstrated comparable survival 
outcomes for patients treated with primary radiother-
apy2,10–12. However, those studies are limited by institu-
tional selection bias, incomplete surgical data, and lack 
of laryngectomy-free survival (lfs) as an outcome2,10–12. 
Whether radiation is equivalent to primary laryngectomy 
as a treatment option remains unknown. Similarly, there 
is no evidence to suggest that the apparent increased use 
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of radiotherapy over time has resulted in an improvement 
in lfs in this patient population.
The purpose of the present study was to report over-
all survival (os) and lfs outcomes for patients diagnosed 
with subglottic scc in Ontario over a 15-year period and 
to determine whether primary laryngectomy results in an 
improved os.
METHODS
Study Design and Setting
Residents of Ontario (2014 population estimate: 13, 678,700)13 
have universal access to hospital care and physician 
services. Those encounters are recorded in large popu-
lation-based health care databases, many of which are 
held at the Institute for Clinical Evaluative Sciences. We 
conducted a population-based retrospective cohort study 
of all patients with laryngeal carcinoma. The study was 
approved by the Sunnybrook Health Sciences Centre re-
search ethics board.
Data Sources
We used five linked databases: the Ontario Cancer Registry, 
which records data for all patients with non-skin cancers 
diagnosed in Ontario (mandatory reporting)14,15; the Dis-
charge Abstract Database held by the Canadian Institute 
for Health Information, which records all admissions to 
hospitals and includes information about diagnoses and 
procedures performed; the ohip (Ontario Health Insurance 
Plan) database, which contains information about all fee-
for-service physician claims for inpatient and outpatient 
services; the Registered Persons Database, which contains 
vital statistics about all permanent residents of Ontario; 
and the National Ambulatory Care Reporting System Data- 
base, which collects data about ambulatory care visits, 
including day surgery, outpatient clinics, cancer clinics, 
and emergency department visits. The databases were 
linked using unique encoded identifiers (encrypted On-
tario health care numbers that are unique to each resident 
eligible for health care services paid by the government) 
available starting July 1991, after the assignment of new 
health care numbers in Ontario.
We previously used those data sources to study sec-
ular trends in other conditions16,17. For the present work, 
we used the Ontario Cancer Registry to identify laryngeal 
cancer patients (subsite subglottis), and the Discharge 
Abstract Database, National Ambulatory Care Reporting 
System, ohip database, and Registered Persons Database 
to define patient characteristics, baseline comorbidities, 
and patient outcomes. Diagnoses were identified using 
the codes defined by the International Classification of 
Diseases, 9th revision (pre-2002), and 10th revision (post-
2002). Procedures were identified using the codes defined 
in the Canadian Classification of Diagnostic, Therapeutic, 
and Surgical Procedures (pre-2002) and the Canadian 
Classification of Health Interventions (post-2002).
Patients
All patients with a diagnosis of laryngeal cancer and scc on 
histology during 1995–2009 in the province of Ontario were 
retrospectively reviewed. To allow for a complete 3-year 
look-back for baseline comorbidities, cohort accrual began 
1 January 1995. We restricted the cohort to patients who were 
residents of Ontario and who had a histologic diagnosis of 
scc. A prior validation study found a sensitivity of 89.8% and 
a positive predictive value of 96.8% for the diagnostic code 
for laryngeal cancer in the registry compared with a clinical 
database18. The date of the laryngeal cancer diagnosis (“in-
dex date”) served as the start time for follow-up.
Patients were further divided into groups for supra-
glottic, glottic, and subglottic cancers. Staging data were 
available only for the subpopulation diagnosed from 2005 
to 2009. Registry staging ranged from i to iv and was derived 
from the American Joint Committee on Cancer staging 
manual (6th or 7th edition)4. We classified patients with 
stage I or ii disease as “early stage.” According to both 
versions of the staging manual, the early-stage grouping 
included patients with local disease only and excluded 
patients with regional or distant metastases. Patients with 
stage iii or iv disease were classified as “advanced stage.” 
That group included patients with advanced local disease 
and patients with regional or distant metastasis. Patients 
who underwent laryngectomy within 3 months of the initial 
diagnosis were considered to be have been treated with 
primary laryngectomy. We assumed that 3 months would 
allow enough time to capture patients whose treatment was 
delayed for other medical problems, but would be too soon 
for radiation failure to be identified (assuming 6- to 7-week 
course of radiation). Patients who underwent laryngectomy 
after 3 months were considered to have experienced radio-
therapy failure requiring a salvage laryngectomy. Those not 
treated with primary laryngectomy were assumed to have 
been treated with primary radiation.
Outcomes
We categorized the study period into three eras: 1995–1999, 
2000–2004, and 2005–2009. We selected those eras to cor-
respond to the availability of staging data, which began in 
2004. Thus, the cohort was allocated into 3 approximately 
equal periods. We determined 5-year mortality after a 
subglottic cancer diagnosis for each of the 3 eras and the 
rate per 100 person–years. We assessed 2 primary outcomes 
in the 5 years after a new diagnosis of laryngeal cancer: os 
and lfs. We defined os as the proportion of patients alive 
at 5 years from the date of diagnosis, censoring for patients 
who were lost to follow-up before 5 years. We defined lfs as 
the proportion of patients alive at 5 years from the date of 
diagnosis with an intact larynx, censoring for patients who 
were lost to follow-up. Deaths (including out-of-hospital 
mortality) are well ascertained in the Registered Persons 
Database, which provides accurate mortality data for all 
Ontario residents19.
Statistical Analysis
For each of the defined eras and for the 15-year overall 
period, mean age with standard deviation, age group (≤64 
years, ≥65 years), sex, Charlson comorbidity group (0, 1, 
≥2), and treatment (laryngectomy, salvage laryngecto-
my, radiation) are reported. To determine whether the 
demographic characteristics of the patients differed in 
each era, the Kruskal–Wallis test for continuous variables 
was applied.
SURVIVAL IN SUBGLOTTIC CANCER, MacNeil et al.
e571Current Oncology, Vol. 25, No. 6, December 2018 © 2018 Multimed Inc.
We determined the crude 5-year mortality for patients 
after a subglottic cancer diagnosis and calculated the rate 
per 100 person–years. Kaplan–Meier plots adjusting for age 
group, Charlson comorbidity group, and sex (male/female) 
were generated for both 5-year os and 5-year lfs.
For the patients in each of the 3 eras, Kaplan–Meier 
plots were generated for both 5-year os and 5-year lfs. We 
used the log-rank test to determine whether a difference 
was evident between the 3 eras for each survival outcome.
We used the PHREG procedure in the SAS software 
application (version 9.3: SAS Institute, Cary, NC, U.S.A.) 
to create a Cox proportional hazards regression model 
investigating the association between treatment with 
surgery or radiation and survival, adjusting for the in-
fluence of potential confounders (age, sex, and Charlson 
comorbidity group).
SAS was used for all statistical analyses. We interpreted 
2-tailed p values less than 0.05 as statistically significant.
RESULTS
Cohort Description and Demographics
From 1995 to 2009, 4977 patients in Ontario were diagnosed 
with laryngeal cancer. Of that group, 50 patients were 
excluded because of insufficient information, leaving 
4927 patients, 1371 of whom (27.83%) were diagnosed 
supraglottic cancer; 3201 (64.97%), with glottic cancer; and 
89 (1.81%), with subglottic cancer (Figure 1).
Of the 89 patients with subglottic cancer, 31 were 
diagnosed during 1995–1999, 31 during 2000–2004, and 
27 during 2005–2009. Table i reports the baseline charac-
teristics of those patients. Mean age at diagnosis was 68 
years, and 68 of the patients were men (76.4%). Primary 
laryngectomy was used to treat 13 patients (14.6%); 15 
patients (16.9%) underwent salvage laryngectomy; and 61 
patients (68.5%) did not undergo laryngectomy within 5 
years of diagnosis. The number of patients who underwent 
laryngectomy did not differ in the 3 eras (p = 0.23).
Five-Year Survival Trends
Table ii outlines the 5-year mortality after a diagnosis of 
subglottic cancer. The 5-year mortality was 58.06% (18/31) 
during 1995–1999, 41.94% (13/31) during 2000–2004, and 
59.26% (16/27) during 2005–2009. Mortality rates were not 
significantly different in the 3 diagnosis eras (p = 0.42). For 
the cohort overall, the 5-year os was 47.2%, and the 5–year 
lfs was 31.5% (Figures 2 and 3).
Survival Analysis
Results of the survival analysis indicate that age (≥65 years 
vs. ≤64 years) is a significant predictor of 5-year mortality 
(hazard ratio: 2.57; 95% confidence interval: 1.25 to 5.26; 
Table iii). No significant difference in 5-year mortality was 
observed for patients treated with primary laryngectomy 
compared with those treated with primary radiation 
(hazard ratio: 1.21; 95% confidence interval: 0.55 to 2.67).
DISCUSSION
In the Canadian province of Ontario, subglottic scc repre-
sented 1.8% of all new diagnoses of laryngeal cancer during 
1995–2009. The 5-year os for the subglottic site was 47.2% 
compared with 57.4% for the other laryngeal subsites16. 
During the 15-year period of interest, we observed no 
improvement in os or lfs. Furthermore, we found no dif-
ference in survival between patients treated with primary 
laryngectomy and those treated with primary radiotherapy.
FIGURE 1 Selection of patients for the subglottic cancer cohort.
TABLE I Baseline characteristics of 89 patients in Ontario with 
subglottic squamous cell cancer, 1995–2009
Variable Value
Mean age (years) 68.0±11.1
Age group [n (%)]
<65 Years 32 (35.9)
≥65 57 (64.0)
Sex [n (%) men] 68 (76.4)
Stagea (n)
I/II 12
III/IV ≤15
Treatment [n (%)]
Primary laryngectomyb 13 (14.6)
Radiationc 61 (68.5)
Salvage laryngectomyd 15 (16.9)
a Staging information was available only for 2005–2009.
b  Defined as patients undergoing laryngectomy within 3 months of 
the date of diagnosis.
c  Radiation codes were unavailable. We therefore assumed that, if 
patients did not undergo primary laryngectomy, they had been 
treated with radiation. However, patients who received no treatment 
might also have been included in this group.
d  Defined as patients undergoing laryngectomy more than 3 months 
after the date of diagnosis.
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Subglottic Carcinoma Characteristics
The demographic characteristics of the study patients 
are consistent with those reported in other studies, 
demonstrating the face validity of the present work1,5,16,20. 
Subglottic carcinoma in our cohort represented 1.8% of 
all laryngeal sccs. Other studies have found incidence 
rates in the range of 1.0%–8.7% for subglottic laryngeal 
scc, although most studies report a range 1%–1.6%5,20,21. 
Variability in the definition of primary subglottic scc over 
time and the inclusion of cancers of other histology in 
the definition of subglottic scc is the likely reason for the 
discrepancy in the incidence reported here compared with 
other series10,21–23.
Primary subglottic carcinoma is usually asymptomatic 
early in the disease process and is traditionally thought to 
present at an advanced stage (50%–64% of patients)2,5,8,11. 
However, we found an even distribution between patients 
presenting with early-stage and advanced-stage disease. 
The small number of patients in our series and lack of 
staging information before 2005 probably accounts for 
the variability in stage presentation. The largest reported 
study of patients with subglottic scc demonstrated a 58.4% 
(219/375) rate of advanced-stage presentation11. Taken 
together, those data indicate that patients are slightly 
more likely to present with advanced-stage than with early- 
stage disease.
Subglottic Carcinoma Treatment
The treatment options for primary subglottic carcinoma 
include surgery (laryngectomy or partial laryngectomy), 
radiation (with or without chemotherapy), or combination 
therapy. Direct extra-laryngeal extension, a circumferen-
tial pattern of intraluminal spread and cartilage invasion, 
means that few patients are candidates for partial laryn-
gectomy as primary treatment24. With a few exceptions 
(patients undergoing partial or hemi-laryngectomy), most 
patients in other studies underwent total laryngectomy 
(Table iv). Other studies showed significant variability 
with respect to primary treatment administered (Table iv). 
In some studies, patients were treated with primary sur-
gery1,11,25,27; in others, most patients were treated with pri-
mary radiotherapy10,12,20,26,28. Furthermore, the indications 
for combined-modality treatment, adjuvant radiation, and 
salvage laryngectomy were often not reported.
In our study, 13 patients (14.6%) underwent primary 
laryngectomy. Other reports in the literature describe 
FIGURE 2 Kaplan–Meier plot depicting 5-year laryngectomy-free 
survival.
FIGURE 3 Kaplan–Meier plot depicting 5-year overall survival.
TABLE III Mortality at 5 years after a diagnosis of subglottic squamous 
cell carcinoma
Variable Adjusted HR 95% CI
Age group
<65 1.0 (Reference)
≥65 2.57 1.25 to 5.26
Sex
Women 1.0 (Reference)
Men 1.26 0.62 to 2.56
CCI group
0 1.0 (Reference)
1 1.09 0.32 to 3.67
≥2 1.97 0.86 to 4.50
Treatment group
Radiation 1.0 (Reference)
Primary laryngectomy 1.21 0.55 to 2.67
HR = hazard ratio; CI = confidence interval; CCI = Charlson comorbidity 
index.
TABLE II Five-year mortality after a diagnosis of subglottic cancer
Diagnosis
period
Patients
(n)
5-Year mortality
[n (%)]
Deaths per
100 person–years
1995–1999 31 18 (58.1) 19
2000–2004 31 13 (41.9) 12
2005–2009 27 16 (59.3) 20
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TABLE IV Subglottic carcinoma treatment and survival outcomes in the literature
Reference Patients
(n)
Stage Treatment OS
(5-year %)
Group (n) Protocol (n)
Vermund, 19703,a 185 NR TLa 58 42
RT 127 36
Shaha and Shah, 198225 16 I/II 3 TL 13 70
III/IV 13 PL 3
Warde et al., 198726 23 I/II 9 RT 22 26
III/IV 14 RT with sTL 1
Guedea et al., 199112 6 I/II 3 RT 4 33
III/IV 3 RT with sTL 2 (4-year %)
Haylock and Deutsch, 199320 23 I/II 13 RT 21 58
III/IV 10 RT with sTL 2
Dahm et al., 199822 28 I/II 19 TL 10 58c
III/IV 9 TL with aRT 1
PL 2
PL with aRT 2
RT 10
RT with salvage Sx 2
Palliation 1
Strome et al., 19992 10d I/II 5 TL with aRT 3 67
III/IV 4 RT 6
Santoro et al., 200027 49 I/II 17 TL 17 56e
III/IV 32 TL with aRT 18
RT 6
Palliation 8
Paisley et al., 200210 43 I/II 23 RT 29 50
III/IV 20 RT with sTL 13
CRT 1
Garas and McGuirt, 20061 15 I/II 3 TL 3 25f
III/IV 12 TL with aRT 6
RT 4
RT with sTL 2
Smee et al., 20085 10 I/II 6 TL 1 70
III/IV 4 TL with aRT 4
PL with aRT 1
RT 4
Hata et al., 201328 19 I/II 9 RT 5 80g
III/IV 10 CRT 14
Marchiano et al., 201611 889 I/II 126 Sxh 139 41.5
III/IV 219 RT 277
Sxh with RT 317
Palliation 85
Unknown 71
Present study 89 I/II 12 TL 13 47
III/IV 12 RT 76
a  Literature review, including 20 studies. Some patients received adjuvant treatment.
c  No difference in survival between treatment groups. The 5-year overall survival was 44% for RT alone, 50% for surgery alone, and 100% for 
combined therapy.
d Staging was unavailable for 1 patient.
e  The 5-year overall survival for patients treated with RT alone, with TL alone, or with TL and aRT was 0%, 47%, and 83.3% respectively. Survival 
was statistically significantly different for patients receiving TL with aRT compared with those receiving TL alone or RT alone (p = 0.001).
f  The 3-year overall survival was 0% for patients treated with TL, 40% for those treated with TL and aRT, 33.3% for those treated with RT, and 0% 
for those treated with RT and sTL.
g  The 5-year overall survival was 100% for patients treated with CRT and 92% for those treated with RT.
h  Population-based study using U.S. Surveillance, Epidemiology, and End Results data that provided no further detail about the extent of surgery.
OS = overall survival; NR = not reported; TL = total laryngectomy; RT = radiation therapy; PL = partial laryngectomy; sTL = salvage total laryngectomy; 
aRT = adjuvant radiation therapy; Sx = undefined surgery; CRT = chemoradiation therapy.
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31% –81% of patients being treated with primary total 
laryngectomy and 10% –30% of patients being treated 
with partial laryngectomy1–3,5. We were not able to de-
termine whether any patients in our cohort underwent 
partial laryngeal surgery. In our cohort, 68.5% of patients 
were managed non-surgically. Other studies reported 
12%–100% of patients being treated with primary radio-
therapy1–3,5,10,12,20,28. We did not have access to radiation 
or chemotherapy billing codes, and we therefore assumed 
that, if patients did not receive primary laryngectomy, they 
were treated with radiation. However, some of the latter 
patients could have been treated with palliative intent. 
Our reported rate of salvage laryngectomy was 16.9%, but 
that number might have been larger, because some of the 
patients in the denominator might have been palliated. 
Data from our study and others do not make clear what pro-
portion of patients treated with primary radiation required 
salvage laryngectomy and whether organ-preservation 
protocols improve lfs.
Survival Outcomes
We report a 5-year os of 47.2% for the overall group of pa-
tients with a diagnosis of subglottic scc. Previous studies 
have reported 5-year os rates ranging from 25% to 80% 
(Table iv). Some authors have suggested that a higher rate 
of local recurrence, particularly at the peristomal region, 
or a high rate of distant metastatic spread up to 32% is 
responsible for the poor os; however, the data are un-
clear22. Earlier studies (Table iv) suggest that combined- 
modality treatment—either surger y plus radiation, 
chemotherapy plus radiation, or radiation followed by 
salvage surgery—offers a survival benefit. However, small 
sample sizes prevent definitive conclusions from being 
drawn2,5,28. Limitations in our databases meant that we 
were unable to determine whether patients in our cohort 
received combined-modality treatment. Our results do, 
however, suggest that primary laryngectomy might not 
provide a survival benefit.
We observed no change in os or lfs from 1995 to 
2009 (Figures 1 and 2). Those results are consistent with 
prior work by our group and others demonstrating no 
change in os in patients with glottic and supraglottic 
carcinomas16,29–31. Although large randomized trials have 
demonstrated an improved lfs for patients with glottic 
and supraglottic carcinoma treated with concurrent 
chemoradiation, that benefit has not been demonstrated 
in population-based studies16,29,30. The reasons for the 
discrepancy are unknown, but could be related to patient 
selection for laryngeal-preservation protocols. Addition-
ally, the difficulty in differentiating primary subglottic 
carcinoma from glottic carcinoma with subglottic exten-
sion and the evolving definition of the superior boundary 
of the subglottis could have influenced survival trends 
over the study period.
Strengths and Limitations
To our knowledge, the present study is the largest re-
ported in the literature assessing the outcome of lfs in 
patients with subglottic carcinoma. Our survival outcome 
is robust, accounting for all patients with a diagnosis of 
subglottic carcinoma in the province of Ontario. That is, 
no selection bias is inherent in institutional reviews of 
survival outcomes. Procedural and diagnostic codes were 
well-documented18.
However, our study has limitations. We had only 
T stage and N stage information available for 2005–2009, 
and thus the stage analysis was limited. Furthermore, 
disease-specific survival was not calculated because cause 
of death has a low sensitivity in cancer registries and pop-
ulation databases. We assumed that patients who did not 
receive a primary laryngectomy were treated with primary 
radiation. Some of those patients might have been treated 
with palliative intent or might have received no treatment. 
Lack of radiation and chemotherapy treatment codes lim-
ited the analysis.
CONCLUSIONS
Compared with other laryngeal cancer subsites, subglottic 
carcinoma has a low incidence and a poor prognosis. The 
reason for poor os in patients with this subsite of laryngeal 
cancer is unknown, but appears to have no association with 
advanced stage at presentation. Overall, we observed no 
difference in the 5-year mortality rate for patients treated 
with primary laryngectomy and those treated without 
laryngectomy. Thus laryngeal preservation therapy could 
be considered a primary option for suitable patients. More 
research is needed to determine which patients are suitable 
for laryngeal-preservation treatment protocols and which 
should receive primary laryngectomy.
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